Literature DB >> 23887306

Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E.

Ildiko Mesteri1, Günther Bayer1, Jochen Meyer2, David Capper2, Sebastian F Schoppmann3, Andreas von Deimling2, Peter Birner4.   

Abstract

BRAF V600E mutation in serrated lesions of the colon has been implicated as an important mutation and as a specific marker for the serrated carcinogenic pathway. Recent findings point to microvesicular hyperplastic polyps that have similar histologic and molecular features to sessile serrated adenomas/polyps, as potential colorectal carcinoma precursors. The aim of this study was to evaluate BRAF V600E mutation status by immunohistochemistry in serrated lesions of the colon with regard to histomorphology. We investigated 194 serrated lesions of the colon, comprising 42 sessile serrated adenomas/polyps, 16 traditional serrated adenomas, 136 hyperplastic polyps and 20 tubular/tubulovillous adenomas (conventional adenomas) with the novel BRAF V600E mutation-specific antibody VE1. In addition, BRAF exon 15 and KRAS exon 2 status was investigated by capillary sequencing in selected cases. All sessile serrated adenomas/polyps (42/42, 100%), 15/16 (94%) traditional serrated adenomas and 84/136 (62%) hyperplastic polyps were VE1+. None of the VE1- serrated lesions showed BRAF V600E mutation. Forty out of 42 (95%) sessile serrated adenomas/polyps displayed areas with microvesicular hyperplastic polyp-like features. In microvesicular hyperplastic polyps, VE1 positivity was significantly associated with nuclear atypia (P=0.003); however, nuclear atypia was also present in VE1- cases. Immunostaining with VE1 allows not only the detection of BRAF V600E mutation but also the correlation with histomorphology on a cellular level in serrated lesions. VE1 enables a subclassification of microvesicular hyperplastic polyps according to the mutation status. This improved classification of serrated lesions including immunohistochemical evaluation of BRAF V600E mutation may be the key to identify lesions with higher potential to progression into sessile serrated adenoma/polyp, and further to BRAF V600E-mutated colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23887306     DOI: 10.1038/modpathol.2013.126

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  18 in total

1.  A cautionary note on the immunohistochemical detection of BRAF v600e mutations in serrated lesions of the colon.

Authors:  Nicole C Panarelli; Anna-Sophie Weidner; Rhonda K Yantiss; Yao-Tseng Chen
Journal:  Mod Pathol       Date:  2015-05       Impact factor: 7.842

Review 2.  BRAF mutation as a potential marker to identify the proximal colon serrated polyps with malignant potential.

Authors:  Xiangsheng Fu; Xiaoyan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.

Authors:  Takafumi Naito; Katsuhiko Nosho; Miki Ito; Hisayoshi Igarashi; Kei Mitsuhashi; Shinji Yoshii; Hironori Aoki; Masafumi Nomura; Yasutaka Sukawa; Eiichiro Yamamoto; Yasushi Adachi; Hiroaki Takahashi; Masao Hosokawa; Masahiro Fujita; Toshinao Takenouchi; Reo Maruyama; Hiromu Suzuki; Yoshifumi Baba; Kohzoh Imai; Hiroyuki Yamamoto; Shuji Ogino; Yasuhisa Shinomura
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity.

Authors:  Jacob R Bledsoe; Michal Kamionek; Mari Mino-Kenudson
Journal:  Am J Surg Pathol       Date:  2014-10       Impact factor: 6.394

5.  VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma.

Authors:  Sara Sajanti; Päivi Sirniö; Juha P Väyrynen; Anne Tuomisto; Kai Klintrup; Jyrki Mäkelä; Ari Ristimäki; Markus J Mäkinen
Journal:  Virchows Arch       Date:  2014-04-11       Impact factor: 4.064

6.  Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics.

Authors:  Tilman T Rau; Abbas Agaimy; Anastasia Gehoff; Carol Geppert; Klaus Jung; Katharina Knobloch; Cord Langner; Alessandro Lugli; Irene Groenbus-Lurkin; Iris D Nagtegaal; Josef Rüschoff; Xavier Saegert; Mario Sarbia; Regine Schneider-Stock; Michael Vieth; Ellen C Zwarthoff; Arndt Hartmann
Journal:  Virchows Arch       Date:  2014-04-12       Impact factor: 4.064

7.  Claudin-1 Expression Is Elevated in Colorectal Cancer Precursor Lesions Harboring the BRAF V600E Mutation.

Authors:  Maria Caruso; Kim Y C Fung; James Moore; Gemma V Brierley; Leah J Cosgrove; Michelle Thomas; Glenice Cheetham; Emma Brook; Louise M Fraser; Teresa Tin; Ha Tran; Andrew Ruszkiewicz
Journal:  Transl Oncol       Date:  2014-06-19       Impact factor: 4.243

8.  Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique.

Authors:  Mark Kriegsmann; Norbert Arens; Volker Endris; Wilko Weichert; Jörg Kriegsmann
Journal:  Diagn Pathol       Date:  2015-07-30       Impact factor: 2.644

Review 9.  Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF.

Authors:  Alexandra Thiel; Ari Ristimäki
Journal:  Front Oncol       Date:  2013-11-15       Impact factor: 6.244

10.  Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.

Authors:  Katerina Dvorak; Birte Aggeler; John Palting; Penny McKelvie; Andrew Ruszkiewicz; Paul Waring
Journal:  Pathology       Date:  2014-10       Impact factor: 5.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.